Related references
Note: Only part of the references are listed.Ozoralizumab, a Humanized Anti-TNFα NANOBODY(R) Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG
Chihiro Ishiwatari-Ogata et al.
FRONTIERS IN IMMUNOLOGY (2022)
Ozoralizumab for rheumatoid arthritis
Jennifer Thorley
LANCET RHEUMATOLOGY (2022)
Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis
Tsutomu Takeuchi et al.
ARTHRITIS & RHEUMATOLOGY (2022)
The role of IgG Fc receptors in antibody-dependent enhancement
Stylianos Bournazos et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Drug Hypersensitivity Diagnosis, Genetics, and Prevention
Ruwen Boehm et al.
DEUTSCHES ARZTEBLATT INTERNATIONAL (2018)
Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins
Zuben E. Sauna et al.
TRENDS IN BIOTECHNOLOGY (2018)
Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015
Toshinobu Matsui et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2017)
Pathogenetic insights from the treatment of rheumatoid arthritis
Iain B. McInnes et al.
LANCET (2017)
Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments
Elena Krayukhina et al.
MABS (2017)
Why the Immune System Should Be Concerned by Nanomaterials?
Marc J. Pallardy et al.
FRONTIERS IN IMMUNOLOGY (2017)
Bivalent llama single-Domain antibody Fragments against Tumor necrosis Factor have Picomolar Potencies due to intramolecular interactions
Els Beirnaert et al.
FRONTIERS IN IMMUNOLOGY (2017)
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes
Murli Krishna et al.
FRONTIERS IN IMMUNOLOGY (2016)
Immobilized Immune Complexes Induce Neutrophil Extracellular Trap Release by Human Neutrophil Granulocytes via FcγRIIIB and Mac-1
Martina Behnen et al.
JOURNAL OF IMMUNOLOGY (2014)
Immunogenicity/Hypersensitivity of Biologics
Michael W. Leach et al.
TOXICOLOGIC PATHOLOGY (2014)
Selective TNF-α inhibitor-induced injection site reactions
Giuseppe Murdaca et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Isoflurane inhibits neutrophil recruitment in the cutaneous Arthus reaction model
Carla Carbo et al.
JOURNAL OF ANESTHESIA (2013)
Impact of Immune Complex Size and Glycosylation on IgG Binding to Human FcγRs
Anja Lux et al.
JOURNAL OF IMMUNOLOGY (2013)
Neutrophils in local and systemic antibody-dependent inflammatory and anaphylactic reactions
Friederike Joensson et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses
Marisa K. Joubert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Aggregation, immune complexes and immunogenicity
Roy Jefferis
MABS (2011)
Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy
Jennifer Barton
Patient Preference and Adherence (2010)
Mechanisms of Immune Complex-Mediated Neutrophil Recruitment and Tissue Injury
Tanya N. Mayadas et al.
CIRCULATION (2009)
GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation
Berk Hess et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms
Min-Soo Kim et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE
Jane Tian et al.
NATURE IMMUNOLOGY (2007)
Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs
Tadahiko Kohno et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2007)
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis
Honghui Zhou et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Formatted anti-tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis
Ken Coppieters et al.
ARTHRITIS AND RHEUMATISM (2006)
Fc receptors and their interaction with complement in autoimmunity
RE Schmidt et al.
IMMUNOLOGY LETTERS (2005)
Myeloperoxidase: friend and foe
SJ Klebanoff
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial
EHS Choy et al.
RHEUMATOLOGY (2002)
Binding and functional comparisons of two types of tumor necrosis factor antagonists
B Scallon et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
